Related Experiment Videos
Biologicals and vaccines: regulatory perspectives
Developments in Biological Standardization
|January 1, 1986
Summary
New biotechnology enables potent pharmaceutical products. Regulatory review focuses on safety and efficacy, including novel cell substrates and genetic engineering considerations for drug approval.
Area of Science:
- Biotechnology
- Pharmaceutical Sciences
- Regulatory Science
Background:
- Biotechnology advancements yield highly pure and potent pharmaceutical products.
- Regulatory approval hinges on demonstrating safety and efficacy.
- Novel production methods, including abnormal mammalian cell substrates, present unique challenges.
Purpose of the Study:
- To discuss appropriate safety testing for new biotechnological products.
- To address novel safety concerns associated with abnormal mammalian cell substrates.
- To evaluate the necessity of efficacy studies for genetically engineered products.
Main Methods:
- Review of current regulatory guidelines for pharmaceutical products.
- Analysis of safety testing protocols for biologics and drugs.
- Case study approach for genetically engineered products versus natural counterparts.
Main Results:
- Identification of key safety tests required for novel pharmaceuticals.
- Highlighting specific risks associated with using abnormal mammalian cells in production.
- Assessment of efficacy study requirements based on existing product data.
Conclusions:
- Comprehensive safety evaluations are crucial for new biotechnological drugs.
- Specific attention must be paid to risks from cell substrates.
- Efficacy studies may be streamlined for genetically engineered products with established natural analogs.